SC Ianalumab considered safe, effective in Sjögren's syndrome

Published On 2021-12-11 02:25 GMT | Update On 2021-12-15 05:52 GMT

Findings from a recent trial showed ianalumab to be safe and well-tolerated in patients with moderate to severe primary Sjogren's syndrome. The study was published in the journal The Lancet on November 30, 2021.

Sjögren's syndrome is an immune system disorder characterized by dry eyes and mouth, systemic features, and reduced quality of life. Currently, there are no disease-modifying treatments. A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy.

For more details check out the full story in link below:

Subcutaneous Ianalumab Safe And Effective For Sjogren's Syndrome: Lancet

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SC Ianalumab considered safe, effective in Sjögren's syndrome

Similar News

Low Dose Ketamine Effectively Relieves pain for ED patients: Study Finds

New Nasal Vaccine May Reduce Whooping Cough Spread: Study Reveals

Plastic Waste to Double by 2050 But Study Finds Blueprint to Tackle Plastic Crisis

Neuropathic Pain Medication May Increase Risk of Hip Fracture: Study Finds

Know your Journal- Exclusive Interview with Dr Atul Kulkarni, Editor In Chief, Indian Journal of Critical Care Medicine

Journal Club- Association between blood pressure, body mass index, and age: A data analytic approach

Nocturnal Acid Breakthrough and the role of Vonoprazan - Dr Roy Patankar

WHO Identifies 17 Top Priority Pathogens for New Vaccine Development